Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ CD300e Monoclonal Antibody (UP-H2)
Mouse Monoclonal Antibody
Supplier: Invitrogen™ MA544078
This item is not returnable.
View return policy
Description
This antibody recognizes an extracellular epitope on CD300e / IREM-2, a 32 kDa glycoprotein expressed by mature monocytes and peripheral blood myeloid dendritic cells. Functional application: Stimulation.
CD300e is a member of the glycoprotein family of cell surface proteins expressed on myeloid cells. CD300e interacts with the TYRO protein tyrosine kinase-binding protein and is thought to be involved as an activating receptor. CD300e is expressed on mature myeloid dendritic cells and monocytes, and is down regulated on immature dendritic cells. Further, CD300e interacts with DAP-12, which mediates activating signals. The alloreactive response of naïve T cells has been reported to become enhanced by the activation of CD300e. Diseases associated with CD300e dysfunction include tungiasis and lice infestation.
Specifications
CD300e | |
Monoclonal | |
1 mg/mL | |
PBS with no preservative; pH 7.4 | |
Q496F6 | |
CD300E | |
CD300e-HA-transfected cells. | |
100 μg | |
Primary | |
Human | |
Antibody | |
IgG1 κ |
Flow Cytometry, Functional Assay, Immunoprecipitation, Western Blot | |
UP-H2 | |
Unconjugated | |
CD300E | |
BC034097; CD300 antigen like family member E; CD300 antigen-like family member E; CD300e; CD300e antigen; CD300e molecule; Cd300le; CLM2; CLM-2; CMRF35A5; CMRF35-A5; CMRF35-like molecule 2; CMRF-35-like molecule-1; Immune receptor expressed on myeloid cells 2; IREM2; IREM-2; PIgR2; PIgR-2; poly-Ig receptor 2; polymeric immunoglobulin receptor 2; TREM5 | |
Mouse | |
Protein A | |
RUO | |
342510 | |
4°C, do not freeze | |
Liquid |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction